Jianmin Pharmaceutical GroupLtd Valuation

Q: What is the Fair Price of 600976 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

600976 (CN¥42.5) is trading above our estimate of [[fair value]] (CN¥6.98)

Is 600976 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600976 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600976 (CN¥42.5) is trading above our estimate of fair value (CN¥6.98)

Significantly Below Fair Value: 600976 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600976?

Key metric: As 600976 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600976. This is calculated by dividing 600976's market cap by their current earnings.
What is 600976's PE Ratio?
PE Ratio	15.2x
Earnings	CN¥427.95m
Market Cap	CN¥6.52b

600976 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	28.8x
PEG Ratio	0.7x

Price to Earnings Ratio vs Peers

How does 600976's PE Ratio compare to its peers?

The above table shows the PE ratio for 600976 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	19.2x
603367 Cisen Pharmaceutical	12.3x	n/a	CN¥6.4b
300725 PharmaBlock Sciences (Nanjing)	40x	28.5%	CN¥6.9b
000915 Shandong Wit Dyne HealthLtd	12.4x	11.5%	CN¥6.0b
000411 Zhejiang Int'l GroupLtd	12x	n/a	CN¥5.7b
600976 Jianmin Pharmaceutical GroupLtd	15.2x	22.2%	CN¥6.5b

Price-To-Earnings vs Peers: 600976 is good value based on its Price-To-Earnings Ratio (15.2x) compared to the peer average (18.9x).

Price to Earnings Ratio vs Industry

How does 600976's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 600976 is good value based on its Price-To-Earnings Ratio (15.2x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 600976's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600976 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15.2x
Fair PE Ratio	25.8x

Price-To-Earnings vs Fair Ratio: 600976 is good value based on its Price-To-Earnings Ratio (15.2x) compared to the estimated Fair Price-To-Earnings Ratio (25.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.66

2.6%

14.2%

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.18

-0.4%

15.5%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.2b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.11

-5.1%

14.5%